TL;DR
Findings indicate that insulin increases NF-κB activation in doxorubicin -treated T-47D breast cancer cells and may sustain NF-κB activity against the cytotoxic effects of doxorubicin.
Findings indicate that insulin increases NF-κB activation in doxorubicin-treated T-47D breast cancer cells and may sustain NF-κB activity against the cytotoxic effects of doxorubicin.
Insulin affects the viability of Luminal A breast cancer T-47D cells exposed to doxorubicin, indicating reduced cellular sensitivity to the cytotoxic effects of doxorubicin.
Breast cancer is one of the most common cancers worldwide, with a high incidence rate. Doxorubicin is a chemotherapeutic agent used in breast cancer management. Nevertheless, chemoresistance remains a major challenge in breast cancer chemotherapy. Insulin contributes to chemoresistance through its mitogenic and prosurv...
Radiotherapy (RT) is a widely used treatment modality for breast cancer, but its broad application is limited by the risk of adverse effects, such as the potential for the tumor to develop resistance to RT. Identifying strategies that enhance RT efficacy while minimizing adverse effects is of significant clinical impor...
Findings identify heat-labile, NET-associated components as mediators of breast cancer chemoresistance and support targeting NETs or their downstream signaling pathways to improve chemotherapy response.
Investigating the effects of metformin on key inflammatory cytokines involved in hepatocellular carcinoma progression, as well as on the expression of c-Jun, a key subunit of the AP-1, led to a significant reduction in the levels of IL-6 and IL-8 in HepG2 cells compared to control group.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
